Kenvue Inc. $KVUE Shares Bought by OFI Invest Asset Management

OFI Invest Asset Management raised its stake in Kenvue Inc. (NYSE:KVUE) by 705.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,979 shares of the company’s stock after purchasing an additional 23,630 shares during the period. OFI Invest Asset Management’s holdings in Kenvue were worth $565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after purchasing an additional 10,600,682 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Kenvue by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock worth $613,882,000 after acquiring an additional 633,461 shares in the last quarter. Boston Partners raised its position in shares of Kenvue by 7.4% during the 1st quarter. Boston Partners now owns 25,346,453 shares of the company’s stock worth $606,920,000 after acquiring an additional 1,750,490 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Kenvue by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock worth $597,395,000 after acquiring an additional 2,597,920 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Kenvue by 15.7% during the 1st quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock worth $523,456,000 after acquiring an additional 2,961,716 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 1.0%

KVUE opened at $16.68 on Monday. The firm has a market cap of $32.00 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72. Kenvue Inc. has a 52 week low of $15.47 and a 52 week high of $25.17. The business’s 50 day moving average is $19.15 and its two-hundred day moving average is $21.31. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue’s dividend payout ratio is presently 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. Canaccord Genuity Group cut their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research report on Saturday, September 27th. The Goldman Sachs Group cut their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Bank of America cut their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. Finally, Evercore ISI cut their target price on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a research report on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.